Chemical Property of Atenolol
Chemical Property:
- Appearance/Colour:white to off-white crystalline solid
- Vapor Pressure:3.82E-11mmHg at 25°C
- Melting Point:154 °C
- Refractive Index:1.5110 (estimate)
- Boiling Point:508.049 °C at 760 mmHg
- PKA:9.6(at 25℃)
- Flash Point:261.059 °C
- PSA：84.58000
- Density:1.125 g/cm3
- LogP:1.54330
- Storage Temp.:Store at RT
- Solubility.:H2O: 0.3 mg/mL
- Water Solubility.:13.5mg/L(25 oC)
- XLogP3:0.2
- Hydrogen Bond Donor Count:3
- Hydrogen Bond Acceptor Count:4
- Rotatable Bond Count:8
- Exact Mass:266.16304257
- Heavy Atom Count:19
- Complexity:263
- Purity/Quality:
-
99%, *data from raw suppliers
Atenolol *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xn
- Hazard Codes:Xn,F
- Statements:
22-36/37/38-20/21/22-36-11
- Safety Statements:
22-24/25-36-26-36/37-16
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Drug Classes:Beta-Adrenergic Receptor Antagonists
- Canonical SMILES:CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
- Recent ClinicalTrials:The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability.
- Recent EU Clinical Trials:The RIME-IVF study
- Recent NIPH Clinical Trials:Clinical Significance of Sphingosine-1-Phosphate in the Evaluation of Endothelial Function and Cardiovascular Risk in Hypertension
-
Uses
β-blockers. Clinical application in the treatment of hypertension, angina and arrhythmia. Selective b1 adrenergic receptor agonist, anti-hypertensive, anti-anginal, anti-arrhythmic Atenolol is 2-[4′[2-hydroxy-3-(iso-propylamino)propoxy]phenyl]acetamide
(12.1.7) [11–13].Atenolol is a selective β1-adrenoblocker, or in other words, a cardioblocker. Like acebutol,
atenolol possesses antianginal, antihypotensive, and antiarrhythmic action. It is used for arterial hypotension, preventing attacks of angina, sinus tachycardia, and preventing supraventricular tachyarrhythmia. It is used for preventing angina pectoris.
-
Therapeutic Function
Beta-adrenergic blocker
-
Clinical Use
Beta-adrenoceptor blocker:
Hypertension
Angina
Arrhythmias
-
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: NSAIDs antagonise hypotensive effect.
Anti-arrhythmics: increased risk of myocardial
depression and bradycardia; increased risk of
bradycardia, myocardial depression and AV block
with amiodarone; increased risk of myocardial
depression and bradycardia with flecainide.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Antihypertensives: enhanced hypotensive effect;
increased risk of withdrawal hypertension with
clonidine; increased risk of first dose hypotensive
effect with post-synaptic alpha-blockers such as
prazosin.
Antimalarials: increased risk of bradycardia with
mefloquine.
Antipsychotics enhanced hypotensive effect with
phenothiazines.
Calcium-channel blockers: increased risk of
bradycardia and AV block with diltiazem;
hypotension and heart failure possible with
nifedipine and nisoldipine; asystole, severe
hypotension and heart failure with verapamil.
Cytotoxics: possible increased risk of bradycardia
with crizotinib.
Diuretics: enhanced hypotensive effect.
Fingolimod: possibly increased risk of bradycardia.
Moxisylyte: possible severe postural hypotension.
Sympathomimetics: severe hypertension with
adrenaline and noradrenaline and possibly with
dobutamine.
